LifeTech Scientific - Cera ASD Occluder

  Out-of-Stock 
 
Notify me when available

  • Out stock
  • Free

Pay in installments

Choose your plan:

Current plan: 3Month

Description: 30+3

Down payment: $0.00 (25.00%)

Number of payments: 3

Tax: $0.00

Amount of payment: $0.00

Overpayment: $0.00

Total: $0.00

Current plan: Cash

Description: نقدی

Down payment: $0.00 (0.00%)

Number of payments: 1

Tax: $0.00

Amount of payment: $0.00

Overpayment: $0.00

Total: $0.00

LifeTech Scientific - Cera ASD Occluder

 

Nitinol wire frame coated with Titanium Nitride (TiN)

Decrease the dissolution of nickel ion efficiently, expected safe long-term biocompatibility.

Promote the growth of endothelial tissue, lessen thrombus complication.

Superior superelastic, effectively reduce atrioventricular block occurrence.

 

LifeTech Scientific - Cera ASD Occluder

 Nickel ion concentration in whole blood     

 

LifeTech Scientific - Cera ASD Occluder

Nickel ion concentration in endocardium

 

Cera Animal Study: Compared to Nitinol occluder, the Cera occluder has demonstrated that faster and better growth of endothelial cell and lower risk of thrombus formation. 

 

LifeTech Scientific - Cera ASD Occluder

 

LifeTech Scientific - Cera ASD Occluder

 

Strategic Membrane Selection

The ASD/PFO covered by a PET membrane that minimizes the chance of clot formation and has a small volume to get into lower profile sheath.

The VSD/PDA occluder covered with a PTFE membrane, which has a denser structure suited for high pressure defect.

 

Conform anatomical features of the defect, providing optimal design

3 types of peri-membranous VSD and a muscular VSD devices designed for different kind of VSD.

The ASD waist diameter available ranging from 6 to 42 mm, and the PDA occluder ranging from 0406 to 2224.

 

Cera Clinical study in China

Principal Investigator: Zhang Zhiwei, MD, FACC, Guangdong Cardiac Institute.

Evaluation of efficacy and safety of Cera  septal defect occluder for congenital cardiac detect: A multicenter, randomized and controlled clinical trial.

- 11 medical centers460 cases enrolled (231 Cera , 229 HeartR ).

- Follow up endpoint 1, 3, 6, 12 months.

 

 

Study conclusion

 

The success rate of immediate complete occlusion with Cera occluder is higher than 97.8%.

The results showed that the incidence of residual shunt were relatively less.

The arrhythmia incidence in Cera group is lower than that in HeartR group which as much as 36%.

 

Cera  PM-VSD clinical study in Brazil

 

Principal Investigator: Doctor Raul Arrieta and tutored by Doctor Carlos Pedra.

Prospective, multicenter, non randomized study.

Starting on November 2010.

3 Brazilian institutions, 56 patients.

Follow up endpoint: 1, 3, 6, 12 and 24 months.

 

 

Initial Result

 

The percutaneous closure of peri-membranous ventricular septal defect with Cera Device has showed a safe effect with excellent immediate occlusion and low complication.

 



Reference :

Data sheet

  • Life tech Scientific
  • China

Specific References

New product



Leave a comment about this product

Write your review

LifeTech Scientific - Cera ASD Occluder

Write your review